Physician profile
Ramit Panara
NPI 1407080849
$52,385.51
in general payments reported to CMS, 2019-2025
69 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $2,056 · 2021: $10K · 2022: $15K · 2023: $8,414 · 2024: $3,005 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,897 · Consulting Fee: $1,675 · Travel and Lodging: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,050.00 |
| Food and Beverage | $8,896.51 |
| Consulting Fee | $1,675.00 |
| Travel and Lodging | $138.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,964.39 | 2020-2025 | |
| Pfizer INC. | $8,726.85 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,421.69 | 2020-2025 | |
| Emd Serono, INC. | $1,244.00 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,151.86 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Allergan, INC. | $1,054.71 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $1,010.60 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $985.83 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $725.48 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Amgen INC. | $693.83 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $557.36 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $550.12 | 2019-2023 | |
| Genentech USA, INC. | $522.02 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neurocrine Biosciences, INC. | $432.93 | 2019-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $427.19 | 2019-2025 | Crexont, Rytary |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $406.58 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $374.83 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $263.29 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $261.48 | 2019-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $254.48 | 2019-2025 | |
| Livanova USA, INC. | $249.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $246.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $199.92 | 2019-2020 | |
| Celgene Corporation | $194.70 | 2022-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $187.13 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $186.94 | 2023-2024 | Aptiom |
| Biohaven Pharmaceutical Holding Company Ltd. | $185.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $182.27 | 2023-2025 | Rexulti |
| Sk Life Science, INC. | $159.47 | 2020-2023 | |
| Adamas Pharmaceuticals, INC. | $159.24 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $153.36 | 2019-2022 | |
| Harmony Biosciences LLC | $130.30 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $127.56 | 2022 | |
| Tg Therapeutics, INC. | $126.63 | 2024-2025 | |
| Acorda Therapeutics, INC | $121.95 | 2019 | |
| Horizon Therapeutics Plc | $115.84 | 2021-2023 | Uplizna |
| Abbott Laboratories | $113.29 | 2022 | |
| Ceribell, INC. | $112.19 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Microvention, INC. | $108.41 | 2022 | |
| Upsher-Smith Laboratories LLC | $99.53 | 2020-2021 | |
| Grifols USA, LLC | $96.61 | 2021-2023 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $91.94 | 2021-2024 | |
| Janssen Biotech, INC. | $84.21 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.04 | 2022-2024 | Gammagard Liquid, Hyqvia |
| Zogenix INC. | $65.57 | 2021 | |
| Impel Pharmaceuticals INC. | $63.41 | 2023 | Trudhesa |
| Tanabe Pharma America, INC. | $61.68 | 2020-2023 | |
| Arbor Pharmaceuticals, INC. | $52.28 | 2019-2021 | |
| Averitas Pharma INC. | $46.13 | 2023-2025 | Qutenza |
| Alnylam Pharmaceuticals INC. | $46.05 | 2023-2024 | Onpattro |
| Avanir Pharmaceuticals, INC. | $42.73 | 2019 | |
| Boston Scientific Corporation | $41.12 | 2023-2024 | |
| Csl Behring | $39.96 | 2024 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $38.68 | 2020-2022 | |
| Silk Road Medical, INC. | $38.43 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Life Molecular Imaging Ltd | $37.64 | 2024 | Neuraceq |
| Merz Pharmaceuticals, LLC | $33.84 | 2024 | Xeomin |
| Vertical Pharmaceuticals, LLC | $31.27 | 2019 | |
| Avion Pharmaceuticals | $29.65 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $28.63 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.88 | 2021 | |
| Kyowa Kirin, INC. | $20.14 | 2021 | |
| Kedrion Biopharma, INC. | $20.09 | 2025 | Koate, Kedrab, Gammaked |
| Azurity Pharmaceuticals, INC. | $19.04 | 2025 | Horizant |
| Neurelis, INC. | $16.80 | 2020 | |
| Vanda Pharmaceuticals INC. | $16.70 | 2025 | Ponvory |
| Strongbridge US INC. | $15.00 | 2019 | |
| Corium, LLC | $14.69 | 2023 | Adlarity |
| Bausch Health US, LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramit Panara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.